Plinabulin

Phase 3Small molecule

BBeyondSpring Pharmaceuticals Inc.

Plinabulin is one of 125 small molecule programs targeting Neutropenia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

124

Competitors

Pipeline

Status by Indication[3][1]

Indication

NeutropeniaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Multiple MyelomaActive, not recruiting

Small Cell Lung CancerActive, not recruiting

NeutropeniaPhase 3

Active, not recruiting

Non-Small Cell Lung CancerPhase 1/Phase 2

Active, not recruiting

Multiple MyelomaPhase 2

Active, not recruiting

Small Cell Lung CancerPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Plinabulin

BBeyondSpring Pharmaceuticals Inc.

Phase 3

1 2

Yervoy

Bristol-Myers Squibb

Preclinical

31 3

Gemzar

GGynecologic Oncology Group

Preclinical

72 4

PORTRAZZA

Eli Lilly

Preclinical

8 5

Imjudo

AstraZeneca

Preclinical

5 6

Gilotrif

Boehringer Ingelheim

Preclinical

12 7

Ofev

Boehringer Ingelheim

Preclinical

7 8

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 9

Remeron

OOrganon and Co

Preclinical

1 10

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Multiple Myeloma

NCT05130827

Q4 2029

Phase 3Not yet recruiting

Non-Squamous NSCLC

NCT07361484

Clinical

Trials by Indication[1]

Neutropenia2 trials

Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia

Unknown status·BBeyondSpring Pharmaceuticals Inc.·Phase 3·NCT03294577·221 enrolled

Plinabulin iv Solution in Prevention of TAC Induced Neutropenia

Completed·BBeyondSpring Pharmaceuticals Inc.·Phase 2·NCT04227990·115 enrolled

Patients With Solid Tumors2 trials

Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3

Completed·BBeyondSpring Pharmaceuticals Inc.·Phase 3·NCT03102606·105 enrolled

Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2

Completed·BBeyondSpring Pharmaceuticals Inc.·Phase 2·NCT04345900·55 enrolled

Multiple Myeloma1 trial

Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT05130827·17 enrolled

Non-squamous NSCLC1 trial

Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4)

Not yet recruiting·BBeyondSpring Pharmaceuticals Inc.·Phase 3·NCT07361484·442 enrolled

Advanced Cancers1 trial

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT04902040·19 enrolled

2 more indications

Non-Small Cell Lung Cancer1 trial

Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer

Terminated·UUniversity of Washington·Phase 1/2·NCT02846792·5 enrolled

Small Cell Lung Cancer1 trial

A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer

Completed·SSalma Sabbour·Phase 1/2·NCT03575793·39 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Plinabulin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Plinabulin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Plinabulin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BeyondSpring Pharmaceuticals Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBeyondSpring Pharmaceuticals Inc.

Plinabulin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2029

Trials by Indication[1]

Neutropenia2 trials

Patients With Solid Tumors2 trials

Multiple Myeloma1 trial

Non-squamous NSCLC1 trial

Advanced Cancers1 trial

Non-Small Cell Lung Cancer1 trial

Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News